Suresh S. Ramalingam

Research interests

Publications

• Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00221-0

• Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2307980

• ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.02.003

• First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

  Journal of Thoracic Oncology · 2021 · https://doi.org/10.1016/j.jtho.2021.09.010

• Sotorasib for Lung Cancers with KRAS p.G12C Mutation

  New England Journal of Medicine · 2021 · 10.1056/nejmoa2103695

• KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917239

• Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.08.2100

• Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1913662

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910231

• First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01042

• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1801946

• CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2018.78.3118

• CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

  Annual Review of Medicine · 2018 · 10.1146/annurev-med-012017-043208

• Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

  Journal of Thoracic Oncology · 2018 · https://doi.org/10.1016/j.jtho.2018.09.004

• The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy

  Cancer · 2018 · https://doi.org/10.1002/cncr.31778

• Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

  Journal of Thoracic Oncology · 2017 · https://doi.org/10.1016/j.jtho.2017.04.003

• Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1713137

• Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

  Science · 2017 · 10.1126/science.aaf0683

• Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.70.3223

• Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

  Proceedings of the National Academy of Sciences · 2017 · 10.1073/pnas.1705327114

• Scientific Advances in Lung Cancer 2015

  Journal of Thoracic Oncology · 2016 · https://doi.org/10.1016/j.jtho.2016.03.012

• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1612674

• Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-13-3473

• AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1411817

• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)70054-9

• Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions

  PLoS ONE · 2013 · 10.1371/journal.pone.0081162

• Adenoid cystic carcinoma of the head and neck

  Cancer · 2012 · https://doi.org/10.1002/cncr.27408

• Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.12.5435

Current projects

No projects listed.